MIRA Pharmaceuticals Reports Positive Preclinical Data for Optimized Oral SKNY-1 Formulation

summarizeSummary

MIRA Pharmaceuticals announced positive preclinical results for the optimized oral formulation of SKNY-1, its drug candidate for obesity and addiction, demonstrating favorable pharmacokinetics and a differentiated safety profile.

check_boxKey Events · Product Development and Regulatory · MIRA

• Positive SKNY-1 Formulation Data

  Preclinical studies showed favorable oral bioavailability, reproducible systemic exposure, robust brain penetration, and substantial liver exposure for the optimized oral formulation of SKNY-1.

• Once-Daily Dosing Potential

  Peak plasma concentrations support the potential for convenient once-daily oral dosing, observed approximately six to twelve hours after administration.

• Differentiated Safety Profile

  SKNY-1 did not produce anxiety-related behavioral effects in a validated preclinical model, distinguishing it from earlier CB1-targeting therapies associated with neuropsychiatric adverse effects.

• Strengthens Development Profile

  These pharmacokinetic findings complement previously reported efficacy and behavioral studies, reinforcing SKNY-1's potential as a differentiated oral therapeutic for obesity and addiction.

auto_awesomeAnalysis · MIRA · Life Sciences

This filing provides crucial new preclinical data for SKNY-1, a key drug candidate for obesity and addiction. The demonstrated favorable oral bioavailability, robust brain and liver penetration, and potential for once-daily dosing significantly strengthen its development profile. Importantly, the data also highlights a differentiated safety profile, avoiding the neuropsychiatric side effects seen with earlier CB1-targeting therapies, which is a major de-risking factor for the program. This progress is vital for a clinical-stage micro-cap company, especially given its previous "going concern" status, as it validates the potential of its pipeline.